1. HOME
2. Research Insight
3. Biosimilars Industry - Emerging Trends to Fuel the Global Industry Growth

The biosimilars market is estimated to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. The growth of this market is mainly driven by rising demand for biosimilars in developed and developing countries, favorable reimbursement policies and launch of novel biosimilars in the market.

The biosimilars industry is undergoing rapid evolution, driven by emerging trends and global forecasts.

Emerging trends in the global Biosimilars Market are:

• Increasing Regulatory Pathway Clarity
• Growing Pipeline of Biosimilar Candidates
• Market Expansion in Emerging Economies
• Biosimilar Competition and Price Erosion
• Biosimilar Market Consolidation and Strategic Partnerships
• Biosimilar Adoption in Oncology and Chronic Disease Management

These emerging trends and global forecasts indicate a promising outlook for the biosimilars industry, characterized by continued innovation, market expansion, and enhanced access to affordable biologic treatments worldwide.

To know about the assumptions considered for the study download the pdf brochure

Increasing Regulatory Pathway Clarity:

Regulatory agencies worldwide are providing clearer guidance and pathways for the approval of biosimilars, facilitating market entry and competition. This clarity includes guidelines for demonstrating biosimilarity, interchangeability, and extrapolation of indications.

Future Forecast: Continued harmonization of regulatory standards and processes across regions will streamline biosimilar development and approval, encouraging investment and innovation in the biosimilars market.

Growing Pipeline of Biosimilar Candidates:

The biosimilars pipeline is expanding rapidly, with numerous companies developing biosimilar versions of a wide range of biologic drugs. This pipeline includes biosimilars targeting monoclonal antibodies, insulin, growth factors, and other biologic therapies.

Future Forecast: The increasing number of biosimilar candidates in development indicates a robust pipeline for future market growth. As more reference biologics lose patent protection, opportunities for biosimilar developers to enter the market will continue to expand.

Market Expansion in Emerging Economies:

Emerging economies, including countries in Asia, Latin America, and Eastern Europe, are witnessing increased adoption of biosimilars due to their cost-effectiveness and growing healthcare infrastructure. Governments and healthcare systems in these regions are promoting biosimilar uptake to improve access to biologic therapies.

Future Forecast: The biosimilars market in emerging economies is expected to grow rapidly, driven by rising demand for affordable biologic treatments and supportive regulatory policies. Local manufacturing capabilities and partnerships with multinational companies will further stimulate market expansion in these regions.

Biosimilar Competition and Price Erosion:

Intensifying competition among biosimilar manufacturers is leading to price erosion and cost savings for patients and healthcare systems. Price competition is particularly prominent in markets with multiple biosimilar options for a given reference product.

Future Forecast: Price erosion in the biosimilars market is expected to continue as more competitors enter established therapeutic areas. Biosimilar manufacturers will need to focus on efficiency, innovation, and differentiation to maintain competitiveness and market share.

Biosimilars Market Consolidation and Strategic Partnerships:

Consolidation among biosimilar manufacturers through mergers, acquisitions, and strategic partnerships is reshaping the industry landscape. Larger pharmaceutical companies are entering the biosimilars market through collaborations with specialized biosimilar developers or by acquiring established players.

Future Forecast: Market consolidation and strategic partnerships will accelerate as companies seek to strengthen their biosimilars portfolios, expand geographic presence, and enhance manufacturing capabilities. These alliances will drive further innovation and competitiveness in the biosimilars market.

Biosimilar Adoption in Oncology and Chronic Disease Management:

Biosimilars are gaining traction in oncology and chronic disease management, offering cost-effective alternatives to expensive biologic therapies. Increasing acceptance of biosimilars by healthcare providers and patients, coupled with favorable reimbursement policies, is driving their adoption in these therapeutic areas.

Future Forecast: The oncology and chronic disease segments are expected to be key growth drivers for the biosimilars market. Continued development of biosimilar monoclonal antibodies, growth factors, and other biologics will expand treatment options and improve patient access to essential therapies.

Related Reports:

Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region – Global Forecast to 2028